Susceptibility of Helicobacter pylori to Metronidazole

American Journal of Gastroenterology

Volumn 98, Issue 10, 2003, Pages 2157-2161

  Perna, Federico ^b   Gatta, Luigi ^b   Figura, Natale ^b   Ricci, Chiara ^b   Tampieri, Andrea ^b   Holton, John ^b   Miglioli, Mario ^b   Vaira, Dino ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE;

ADULT; AGAR GEL DIFFUSION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM CULTURE; CONTROLLED STUDY; DIAGNOSTIC TEST; EPSILOMETER TEST; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0142214840     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07681.x     Document Type: Article

References (23)

1. International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. In: International Agency for Research on Cancer (ed). Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC, 1994:177-202.
2. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
3. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93:2330-8.
4. Janssen MJR, Van Oijen AHAM, Verbeek ALM, et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxycillin or a nitromidazole. Aliment Pharmacol Ther 2001;15:613-24.
5. Vakil N, McSorley D, Hahn B, et al. Clarithromycin resistant Helicobacter pylori in the United States. Am J Gastroenterol 1998;93:1432-5.
6. Lind T, Megraud F, Unge P, et al. The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
7. Mégraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
8. Osato MS, Reddy R, Reddy SG, et al. Comparison of the E-Test and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001;17:39-44.
9. Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother 1993;32:45-9.
10. Alarcon T, Domingo D, Lopez-Brea M. Discrepancies between E-Test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori. J Clin Microbiol 1998;36:1165-6.
11. Xia H, Kalantar J, Talley NJ. Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites. J Gastroenterol Hepatol 1998;13:1044-9.
12. van der Wouden EJ, de Jong A, Thijs JC, et al. Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing. Antimicrob Agents Chemother 1999;43:1484-6.
13. Xia H, Keane CT, Beattie S, O'Morain CA. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994;38:2357-61.
14. Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000;4:893-900.
15. Romano M, Iovene MR, Montella F, et al. Pre-treatment antimicrobial-susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000;95:3317-8.
16. Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.
17. Sonnenberg A, Schwartz SJ, Cutler A, et al. Cost savings in duodenal ulcer treatment through H. pylori eradication compared to conventional therapies: Results of a randomized, double-blind, multicenter trial. Arch Intern Med 1998;158:852-60.
18. Chaves S, Gadanho M, Tenreiro R, et al. Assessment of metronidazole susceptibility in Helicobacter pylori: Statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. J Clin Microbiol 1999;37:1628-31.
19. Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001;45:727-33.
20. Dore MP, Osato MS, Realdi G, et al. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother 1999;43:47-54.
21. Berg DE, Gilman RH, Lelwala-Guruge J, et al. Helicobacter pylori populations in Peruvian patients. Clin Infect Dis 1997;25:996-1002.
22. Jorgensen M, Daskalopoulos G. Warburton V, et al. Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: Identification from sequential and multiple biopsy specimens. J Infect Dis 1996;174:631-5.
23. Wong BCY, Wang WH, Berg DE, et al. High prevalence of mixed infections by Helicobacter pylori in Hong Kong: Metronidazole sensitivity and overall genotype. Aliment Pharmacol Ther 2001;15:493-503.